利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.013 秒)

    2-METHYLENE-(17Z)-17(20)-DEHYDRO-19,21-DINOR-VITAMIN D ANALOGS
    2.
    发明公开
    2-METHYLENE-(17Z)-17(20)-DEHYDRO-19,21-DINOR-VITAMIN D ANALOGS 有权
    2-亚甲基 - （17Z）-17（20） - 脱氢-19,21--DINOR-维生素D类似物

    公开(公告)号：EP2313368A2

    公开(公告)日：2011-04-27

    申请号：EP09790206.8

    申请日：2009-07-09

    申请人： Wisconsin Alumni Research Foundation

    发明人： DELUCA, Hector, F. ,  TADI, Bulli, Padmaja ,  PLUM, Lori, A. ,  CLAGETT-DAME, Margaret

    IPC分类号： C07C401/00 ,  A61K31/593 ,  A61P3/04 ,  A61P17/00 ,  A61P17/06 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02

    CPC分类号： C07C401/00 ,  C07C2601/14 ,  C07C2602/24

    摘要： This invention discloses 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs, and specifically 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-1α, 25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has significant calcemic activity in vivo having about the same bone calcium mobilization activity and intestinal calcium transport activity as the native hormone 1α,25-dihydroxyvitamin D3, and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

    17,20(Z)-DEHYDRO VITAMIN D ANALOGS AND THEIR USES
    4.
    发明公开
    17,20(Z)-DEHYDRO VITAMIN D ANALOGS AND THEIR USES 有权
    17,20（Z） - 脱氢 - 维生素D类似物及其用途

    公开(公告)号：EP1817279A2

    公开(公告)日：2007-08-15

    申请号：EP05849730.6

    申请日：2005-11-18

    申请人： WISCONSIN ALUMNI RESEARCH FOUNDATION

    发明人： DELUCA, Hector, F. ,  TADI, Bulli, Padmaja ,  PLUM, Lori, A. ,  CLAGETT-DAME, Margaret

    IPC分类号： C07C401/00 ,  A61K31/59 ,  A61P11/06 ,  A61P17/06 ,  A61P35/00 ,  A61P29/00 ,  A61P37/00

    CPC分类号： C07C401/00 ,  Y02P20/55

    摘要： This invention discloses 17,20(Z)-dehydro vitamin D analogs, and specifically 17(Z)-1a,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also may be used to treat autoimmune disorders and inflammatory diseases in humans as well as renal osteodystrophy and obesity. This compound also has significant calcemic activity making it a therapeutic agent for the treatment or prophylaxis of osteoporosis, osteomalacia, renal osteodystrophy and hypoparathyroidism.

    2-METHYLENE-20(21)-DEHYDRO-19-NOR-VITAMIN D ANALOGS
    7.
    发明公开
    2-METHYLENE-20(21)-DEHYDRO-19-NOR-VITAMIN D ANALOGS 审中-公开
    2-亚甲基-20（21） - 脱氢-19-降 - 维生素-D-ANALOGA

    公开(公告)号：EP2315744A2

    公开(公告)日：2011-05-04

    申请号：EP09790223.3

    申请日：2009-07-09

    申请人： Wisconsin Alumni Research Foundation

    发明人： DELUCA, Hector, F. ,  TADI, Bulli, Padmaja ,  PLUM, Lori, A. ,  CLAGETT-DAME, Margaret

    IPC分类号： C07C401/00 ,  A61K31/593 ,  A61P3/04 ,  A61P17/00 ,  A61P17/06 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02

    CPC分类号： C07C401/00

    摘要： This invention discloses 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19-nor-1α,25-dihydroxyvitamin D
    3 , and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also shows lower activity in vivo on bone calcium mobilization and similar in vivo intestinal calcium transport activity compared to the native hormone 1α,25-dihydroxyvitamin D
    3 , and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.